|
|
|
Insider
Information: |
Hastings Paul J |
Relationship: |
|
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
262,731 |
|
Indirect Shares
|
6,636 |
|
|
Direct
Value |
$367,649 |
|
|
Indirect Value
|
$17,320 |
|
|
Total
Shares |
269,367 |
|
|
Total
Value |
$384,969 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
6
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
5
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-131.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Novelion Therapeutics Inc |
NVLN |
President & CEO, Direc... |
2005-04-29 |
9,500 |
|
0 |
Premium* |
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
2024-06-13 |
12,724 |
2013-05-15 |
0 |
Premium* |
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2014-06-19 |
0 |
Premium* |
|
Protara Therapeutics, Inc |
TARA |
Director |
|
0 |
2016-10-18 |
6,636 |
Premium* |
|
Nkarta, Inc. |
NKTX |
|
2024-03-04 |
240,507 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
PCRX |
Pacira Pharmaceuticals, I... |
Director |
|
2023-05-15 |
4 |
AS |
$41.85 |
$292,950 |
D/D |
(7,000) |
7,179 |
0 |
% |
|
PCRX |
Pacira Pharmaceuticals, I... |
Director |
|
2023-05-15 |
4 |
OE |
$29.90 |
$209,300 |
D/D |
7,000 |
14,179 |
0 |
- |
|
PCRX |
Pacira Pharmaceuticals, I... |
Director |
|
2023-06-05 |
4 |
S |
$38.34 |
$22,237 |
D/D |
(580) |
6,599 |
0 |
% |
|
PCRX |
Pacira Pharmaceuticals, I... |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,775 |
8,374 |
0 |
- |
|
NKTX |
Nkarta, Inc. |
Chief Executive Officer |
|
2023-06-20 |
4 |
S |
$4.85 |
$8,264 |
D/D |
(1,704) |
313,402 |
0 |
- |
|
NKTX |
Nkarta, Inc. |
Chief Executive Officer |
|
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
400,204 |
0 |
- |
|
NKTX |
Nkarta, Inc. |
Chief Executive Officer |
|
2024-01-16 |
4 |
S |
$8.74 |
$84,752 |
D/D |
(9,697) |
390,507 |
0 |
- |
|
NKTX |
Nkarta, Inc. |
Chief Executive Officer |
|
2024-03-01 |
4 |
D |
$13.00 |
$160,654 |
D/D |
(12,358) |
378,149 |
0 |
- |
|
NKTX |
Nkarta, Inc. |
Chief Executive Officer |
|
2024-03-04 |
4 |
D |
$13.33 |
$1,834,768 |
D/D |
(137,642) |
240,507 |
0 |
- |
|
PCRX |
Pacira Pharmaceuticals, I... |
Director |
|
2024-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,230 |
13,604 |
0 |
- |
|
PCRX |
Pacira Pharmaceuticals, I... |
Director |
|
2024-06-13 |
4 |
AS |
$28.38 |
$24,974 |
D/D |
(880) |
12,724 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
President & CEOOfficer |
|
2004-11-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,600 |
|
- |
|
NKTX |
Nkarta, Inc. |
See RemarksOfficer |
|
2020-07-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
253,061 |
|
- |
|
TARA |
Protara Therapeutics, Inc |
Director |
|
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,636 |
|
- |
|
64 Records found
|
|
Page 3 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|